Cyclic Therapeutics

Its proprietary platforms, EvoBind and RareFold, enable blind de novo design of linear and cyclic peptides directly from protein sequence, without requiring target structures, binding sites, or predefined peptide lengths. The models incorporate induced fit and directed evolution in silico and expand the design space beyond the 20 natural amino acids through non-canonical residues. The platform has been experimentally validated across multiple case studies, including high-affinity peptide binders, the first blind sequence-only design of cyclic GPCR agonists, and single-round design of an antiviral cyclic peptide inhibitor.